AMLX Rose 6.8% After Pricing Upsized $500.2M Stock Sale
Amylyx Pharmaceuticals (AMLX) rose 6.8% on Aug 19, 2026 after the company priced an upsized public offering of common stock.
What Amylyx announced
Amylyx said it priced an upsized underwritten public offering of 14,090,000 shares at $35.50 per share. The company also granted underwriters a 30-day option to buy up to an additional 2,113,500 shares at the same public offering price (less underwriting discounts and commissions). All shares in the offering are being sold by Amylyx.
The company said the offering is expected to generate $500.2 million in gross proceeds before underwriting discounts, commissions, and offering expenses, and that figure excludes any exercise of the underwriters’ option. The deal is expected to close on or about Aug 21, 2026, subject to customary closing conditions.
What it means for Amylyx
In plain English: Amylyx is raising a big pile of cash by selling more stock. That kind of financing can give a biotech more runway and flexibility, because it adds capital without taking on debt.
Amylyx said it intends to use the net proceeds together with existing cash, cash equivalents, and marketable securities. While the announcement doesn’t spell out detailed spending line items in the provided summary, the structure signals the company is bolstering its balance sheet and positioning itself to fund operations and priorities with a larger cash cushion.
The offering also being “upsized” suggests demand was strong enough to increase the number of shares sold versus the initial plan, which can matter for how investors interpret the company’s access to capital.
How the stock reacted
AMLX started choppy, then pushed higher through the session.
| Window | Move |
|---|---|
| 5 min | -0.8% |
| 10 min | +1.6% |
| 30 min | +3.4% |
| 1 hour | +6.9% |
| end of day | +6.8% |
On a market-adjusted basis, AMLX outperformed the S&P 500 ETF by 6.9% the same day.